Using 185,360 plasma biomarker measurements collected from 3 independent apremilast Phase III trials in ankylosing spondylitis, psoriasis and psoriatic arthritis, we found IL-17A and KLK-7 as robust biomarkers of psoriasis severity, which were also both biomarkers of general apremilast pharmacodynamic effects across 3 diseases. The gene discussed is IL17A; the disease is ankylosing spondylitis.